HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, ...
Hosted on MSN
Regeneron Inks Deal With Fujifilm Diosynth Biotechnologies To Increase Manufacturing In US: Retail’s Optimistic
Regeneron Pharmaceuticals, Inc. (REGN) announced on Tuesday that it has entered into a manufacturing and supply agreement with contract biopharmaceutical manufacturer FUJIFILM Diosynth Biotechnologies ...
While Fujifilm Diosynth Biotechnologies isn’t immune to the challenges facing the broader CDMO industry, the company’s long-running expansion journey—and its ability to snare high-profile pharma ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A multibillion-dollar agreement ...
Regeneron Pharmaceuticals has announced a new manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies to enhance its production capacity for biologic medicines at Fujifilm's facility ...
Fujifilm Diosynth Biotechnologies' venture into separate small-scale and large-scale business units doesn't appear to be working out as planned. Tuesday, the CDMO revealed that it's reworking its ...
FUJIFILM Diosynth Biotechnologies signed a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals to provide U.S.-based production of its biologic medicines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results